Biotechnology
Trump drops Biden’s proposal for Medicare to cover obesity drugs like Wegovy and Zepbound
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Reuters President Donald Trump on Friday dropped a Biden administration proposal to have Medicare cover obesity drugs, including popular but costly GLP-1 treatments such as Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound. But the Centers […]
Read More
Medicare, Medicaid agency cuts jobs from minority health office, other divisions, as RFK Jr. guts U.S. health department
An aerial of the Centers for Medicare & Medicaid Services building on March 19, 2025 in Woodlawn, Maryland. Kayla Bartkowski | Getty Images The Centers for Medicare & Medicaid Services has slashed jobs from its minority health office and other divisions, CNBC has learned, as Robert F. Kennedy Jr. upends the U.S. health department. During […]
Read More
Pharma tariff relief likely short-lived with sector-specific duties on the horizon
Boxes of Novo Nordisk’s weight-loss drug Wegovy in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters Pharmaceutical companies breathed a sigh of relief Wednesday after U.S. President Donald Trump revealed that they would not be subject to reciprocal tariffs — but that reprieve could prove fleeting as the White House moves ahead with plans […]
Read More
Europe’s pharma industry braces for tariffs as carve-out hopes fade
SEIZED OZEMPIC, WEGOVY AND OTHER WEIGHT LOSS DRUGS AT JFK AIRPORT’S INTERNATIONAL MAIL FACILITY. CNBC COPENHAGEN, Denmark — Europe’s pharmaceutical sector is bracing for the potential impact of U.S. tariffs as hopes of an industry-wide exemption by U.S. President Donald Trump fade. The pharmaceutical industry has until now been exempt from trade levies, but Trump […]
Read More
Novo Nordisk’s diabetes pill slashes risk of cardiovascular complications by 14% after four years
Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with diabetes and heart disease. The pill lowered the risk of cardiovascular-related death, heart attack and stroke by 14% compared to a placebo after four […]
Read More
Top FDA vaccine official Peter Marks resigns in opposition to RFK Jr.
Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration answers a question during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to COVID-19, at the U.S. Capitol in Washington, D.C., May 11, 2021. Greg Nash | Pool | Reuters […]
Read More
Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product’
A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Tom Little | Reuters Copenhagen, DENMARK — Novo Nordisk defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment. CEO […]
Read More
Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Copenhagen, DENMARK — Obesity drug giant Novo Nordisk […]
Read More
Eli Lilly will soon release key data on its weight loss pill. Here’s why it could be a game-changer
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Patients, doctors and investors will soon learn a lot more about a new, more convenient treatment that could shake up the booming weight loss drug market. Eli Lilly plans to […]
Read More
Novo Nordisk’s next-gen obesity drug CagriSema had investors excited. Now they’re not so sure
Medical bottles and syringe are seen with Novo Nordisk logo displayed on a screen in the background. Nurphoto | Nurphoto | Getty Images Novo Nordisk‘s hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from […]
Read More